Gastrointestinal Cancer | Specialty

Preclinical Studies Help to Illuminate Immunotherapy's Role in HCC

November 14th 2016

Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.

Percutaneous and Laparoscopic RFA Outcomes Similar for HCC

November 14th 2016

Similar recurrence-free survival was demonstrated with radiofrequency ablation using percutaneous and laparoscopic methods for patients with hepatocellular carcinoma who were eligible for ablation.

Dr. Tim F. Greten on Immunotherapy in HCC

November 14th 2016

Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute (NCI), discusses the potential for immunotherapy in hepatocellular carcinoma (HCC).

Dr. Hashem El-Serag on the Relationship Between NASH and HCC

November 13th 2016

Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

Biomarkers Define Future Age of Immunotherapy in Cancer

November 13th 2016

The use of immunotherapy as a treatment for cancer is progressively increasing with a flood of recent approvals for immune checkpoint inhibitors directed against CTLA-4 and PD-1.

Lack of Screening, Surveillance Leads to Rising HCC Rates in Hepatitis B Patients

November 13th 2016

Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.

Dr. George N. Ioannou on the Efficacy of Antiviral Agents for Hepatitis C in HCC Patients

November 13th 2016

​George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).

ERK Inhibition May Explain Regorafenib Success in Sorafenib-Resistant HCC

November 13th 2016

Efforts are under way to further evaluate the effects of regorafenib on sorafenib-resistant HCC cells, including the role of suppressing the ERK signaling pathway.

Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant

November 13th 2016

Stevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.

Nivolumab Improves OS in Phase III Gastric Cancer Study

November 11th 2016

Treatment with nivolumab significantly extended overall survival compared with placebo for patients with unresectable, advanced, or recurrent gastric cancer who were refractory or intolerant to standard therapy.

Dr. Venook on Distinguishing Molecular Features in CRC

November 10th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses evolving treatment strategies for patients with colorectal cancer, with regards to molecular features such as sidedness.

FDA Approval Sought for Regorafenib in Advanced Liver Cancer

November 7th 2016

A supplemental new drug application has been submitted to the FDA for the use of regorafenib (Stivarga) as a second-line treatment for patients with unresectable hepatocellular carcinoma.

Dr. Mikhail Fedyanin on Mutation Discordance and Liquid Biopsy in CRC

November 5th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses mutation discordance in the primary tumor and metastases in patients with colorectal cancer (CRC), as well as the benefits of liquid biopsy.

Novel Agents for Gastroesophageal Cancer

November 4th 2016

HER2+ Gastric Cancer

November 4th 2016

Ongoing Research in Gastric Cancer; Antiangiogenic Therapy Upfront and Immunotherapy

November 4th 2016

Treatment for Recurrent Gastroesophageal Cancer

November 4th 2016

Palliative Management for Patients with Gastroesophageal Cancers

November 4th 2016

Maintenance Therapy for Gastroesophageal Cancer

November 4th 2016

HER2-Positive Gastric Cancer

November 4th 2016